Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that physicians are at odds over the advantages of fixed-dose statin combination therapies for the treatment of post-myocardial infarction. According to a new Pharmacor study entitled Post-Myocardial Infarction, physicians who favor these combination therapies state that they will be effective in improving compliance and lipid goal attainment. Those who are skeptical state that such therapies are expensive and limit options for adjusting the dose of individual agents.

"Many experts interviewed believe that Crestor and Merck's Zocor/Merck and Schering-Plough's Zetia single-pill fixed combination will provide additional benefits over current dyslipidemic therapies used in post-myocardial infarction because of their superior low-density lipoprotein (LDL)-lowering efficacy," said Mark Thornton, Ph.D., analyst at Decision Resources. "However, some physicians say that their patients' LDL needs are already met. They cite the lack of proven benefit of Zetia in reducing post-myocardial infarction morbidity and mortality as a barrier to uptake of the combined pill, and they are hesitant to prescribe Crestor because of a lack of long-term safety data and ongoing negative publicity surrounding this statin."

An Increase in the Diagnosis of Post-Myocardial Infarction

An increasing diagnosed prevalent population in the major pharmaceutical countries (United States, France, Germany, Spain, Italy, Japan, and the United Kingdom) is driving the post-myocardial infarction market. Aging populations, increasingly sedentary lifestyles, and improved diagnosis of myocardial infarction will contribute to increases in the prevalent post-myocardial infarction population over the next ten years.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

PPOs to Challenge HMOs for Medicare Business as Patients Are Given More Choice Under New Legislation

View Now